Cordis Corporation Launches SABER™ PTA Dilatation Catheter, a High-Performance Balloon Catheter for PAD

Fremont, Calif., July 1, 2014 – Cordis Corporation announced today the launch of its SABER™ PTA Dilatation Catheter for the treatment of patients with peripheral arterial disease (PAD). The Saber catheter is cleared for use and now available in Europe, the United States and Japan. It offers outstanding crossability and a comprehensive offering of balloon sizes on the widely-used .018” over-the-wire platform. Physicians can now treat a wider range of PAD patients with a single balloon brand.

Developed to complement the Cordis percutaneous transluminal angioplasty (PTA) portfolio as a next-generation, high-performance workhorse .018” PTA balloon catheter, the Saber catheter is intended to dilate stenoses in iliac, femoral, ilio-femoral, popliteal, infrapopliteal and renal arteries and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. The device is also indicated for post-dilation of balloon-expandable and self-expanding stents in the peripheral vasculature.

The Saber catheter is available in balloon diameters of 2-10mm and lengths of 20-300mm. It combines a durable dual layer hydrophilic coating with a low-profile body and new molded tip design to enhance crossability. The catheter has exceptional rated burst pressures of up to 18 atm due to its construction with trusted Duralyn material.

“In my initial experience with the Saber catheter, I see outstanding crossability in very tight lesions as well as excellent deflation times,” said Peter Goverde, MD, ZNA Antwerpen in Brussels, Belgium. “Given these performance characteristics combined with the size offering that the Saber catheter provides, I see the value in adopting this as the preferred .018” workhorse balloon in my practice.”

It is estimated that approximately 27 million people in Western Europe and North America have PAD, which is associated with significant morbidity and mortality.(1)

More information about Cordis Corporation can be found at www.cordis.com.

# # #

Chocolate® is a trademark of TriReme Medical, Inc.

1 Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003 April 28;163(8):884-92.

image description image description
Other News Items